11 Nov 2015 – Press Release: Destiny Pharma Announces Qualified Infectious Disease Product Designation Granted by US FDA for Novel Antibacterial Product In Development for Prevention of Post-Surgical Staphyloccocal Infections
11th November 2015, Brighton, UK – Destiny Pharma Ltd, a leading, clinical stage biopharmaceutical companyfocused on developing and commercialising antibacterial drug products, today announced that the US Food and Drug […]